Immix Biopharma — Primed to pick up the pace in ALA
Immix reported its results for Q325, a period of steady progress for its lead CAR-T asset, NXC-201, in the NEXICART-2 trial for amyloid light chain...
99 Views
Immix Biopharma — NEXICART-2 enrolment progressing well
Immix Biopharma has announced that its US-based NEXICART-2 trial, evaluating lead CAR-T asset NXC-201 in amyloid light chain amyloidosis (ALA), has...
444 Views
Immix Biopharma — $9m private placement to support operations
Immix Biopharma has released a financing and business update, reinforcing its focus on advancing the development of lead CAR-T candidate NXC-201....
478 Views
Immix Biopharma — Fleshing out the CAR-T strategy
Immix has published its Q225 results, reflecting a productive period for NXC-201. The US-based NEXICART-2 trial in relapsed/refractory amyloid...
220 Views
Immix Biopharma — ASCO/KOL event reaffirms NXC-201’s potential
Following Immix’s update at the 61st annual American Society of Clinical Oncology conference (ASCO 2025), the company hosted a key opinion leader...
581 Views